- The Myeloma Beacon - https://myelomabeacon.org -
Istodax (romidepsin)
By: Admin; Published: June 4, 2009 @ 6:51 pm | Comments Disabled
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an enzyme known as histone deacetylase (HDAC). It alters the production of protein from DNA, inhibits the cell cycle, and causes cancer cells to die. Istodax, received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade [1] (bortezomib) in multiple myeloma are underway.
Clinical Trials:
For a list of clinical trials studying Istodax for the treatment of multiple myeloma, see ClinicalTrials.gov [2].
Official Web site for Istodax: http://www.istodax.com/ [3]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/06/04/istodax/
URLs in this post:
[1] Velcade: https://myelomabeacon.org/resources/2008/10/15/velcade/
[2] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=romidepsin+myeloma
[3] http://www.istodax.com/: http://www.istodax.com/
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.